Exscientia (NASDAQ:EXAI) Sets New 52-Week Low at $4.17

Shares of Exscientia plc (NASDAQ:EXAI) reached a new 52-week low during trading on Tuesday . The company traded as low as $4.17 and last traded at $4.27, with a volume of 104490 shares changing hands. The stock had previously closed at $4.36.

Analyst Upgrades and Downgrades

Separately, Bank of America lowered shares of Exscientia from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $11.00 to $9.00 in a research note on Friday, January 5th.

Exscientia Stock Up 1.6 %

The company has a quick ratio of 6.22, a current ratio of 6.22 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $522.24 million, a PE ratio of -2.92 and a beta of 0.78. The business’s 50 day simple moving average is $5.91 and its 200 day simple moving average is $5.85.

Exscientia (NASDAQ:EXAI) last issued its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. As a group, analysts forecast that Exscientia plc will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Exscientia

A number of large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in shares of Exscientia by 65.5% in the 4th quarter. Bank of America Corp DE now owns 5,092 shares of the company’s stock valued at $27,000 after purchasing an additional 2,015 shares during the period. GAMMA Investing LLC increased its holdings in shares of Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after purchasing an additional 2,302 shares during the period. Geode Capital Management LLC increased its holdings in shares of Exscientia by 17.1% in the 1st quarter. Geode Capital Management LLC now owns 18,767 shares of the company’s stock valued at $99,000 after purchasing an additional 2,735 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Exscientia by 101.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,808 shares of the company’s stock valued at $26,000 after purchasing an additional 2,923 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Exscientia by 359.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after buying an additional 4,104 shares during the last quarter. Institutional investors and hedge funds own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.